Ai Mediq is announcing one of the most recent outcomes in our comprehensive program of clinical trials. The results of the application of ReOxy therapy in patients with osteoarthritis and post-covid syndrome has been demonstrated during the online presentation at Eular22 (European Congress of Rheumatology) that takes place in Copenhagen, Denmark. This Year congress will be held in a new format combining both virtual and physical sessions.
The report named “INTERVAL HYPOXIC-HYPEROXIC TRAINING IN REHABILITATION OF PATIENTS WITH OSTEOARTHRITIS AND POST-COVID SYNDROME” will be presented by one of the co-authors, MD, PhD Evgeniya Orlova. The poster POS1453 has been presented via the online platform accessible via link.
The clinical trial enrolling 36 patients has demonstrated that 2-week complex rehabilitation program, including interval hypoxic-hyperoxic training (ReOxy therapy), reduces pain, breathlessness, depression and anxiety, improves functional status and general health in patients with OA and post-COVID syndrome.
